Claims for Patent: 7,862,995

Summary for Patent: 7,862,995

Title:	Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
Abstract:	The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject\'s sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinically positive outcome. Cellular receptors, ligands to those receptors and molecules involved in the programmed cell death pathway are examples of targeted therapy markers that might be used in the present invention.
Inventor(s):	Bacus; Sarah S. (Hinsdale, IL), Hill; Jason (Chicago, IL)
Assignee:	Targeted Molecular Diagnostics (Westmont, IL)
Application Number:	11/223,700
Patent Claims:	1. A method of predicting whether a subject will respond to treatment with a dual tyrosine kinase inhibitor, the method comprising: (a.) analyzing a sample obtained from the subject to determine expression levels for a panel of targeted therapy markers, wherein the panel comprises neu differentiation factor (NDF), P70 S6 kinase protein (P-S6), and insulin-like growth factor-1 receptor (IGF-1R); and (b.) predicting that the subject will be responsive to treatment with the dual tyrosine kinase inhibitor where the sample is NDF positive, P-S6 positive and IGF-1R negative; or predicting that the subject will be non-responsive to treatment with the dual tyrosine kinase inhibitor where the sample is NDF negative, P-S6 negative and IGF-1R positive or NDF negative, P-S6 positive and IGF-1R positive. 2. The method of claim 1, wherein the dual tyrosine kinase inhibitor is trastuzumab or gefitinib. 3. The method of claim 1, wherein the sample is a biopsy sample. 4. The method of claim 1, wherein the sample is from breast cancer tissue. 5. The method of claim 1, wherein the expression levels are measured by a method selected from the group consisting of an enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay (RIA), a Western blot, and an immunohistochemical assay (IHC). 6. The method of claim 1, wherein the expression levels are measured by a method selected from the group consisting of Northern blotting, RT-PCR, and biochip-based methods. 7. The method of claim 1, wherein the panel of targeted therapy markers form a microarray. 8. The method of claim 7, wherein the microarray is a film-based microarray. 9. The method of claim 1, wherein the subject has cancer. 10. A diagnostic kit for predicting the likelihood of successful treatment of cancer with a dual tyrosine kinase inhibitor, the kit comprising: (a.) a panel of targeted therapy markers including neu differentiation factor (NDF), P70 S6 kinase protein (P-S6), and insulin-like growth factor-1 receptor (IGF-1R); and (b.) instructions. 11. The diagnostic kit of claim 10, wherein the panel of targeted therapy markers is present on a microarray.

Details for Patent 7,862,995

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2039-02-26